China names 48 critical foreign drugs to expedite approvals

The Center for Drug Evaluation in China has named 48 drugs on a list of much-needed medicines that it would welcome swift approval applications for – even if they include data from overseas studies.

Where pharma companies can show that outcomes are effective across races on top of data presented to overseas regulators, the center will speedily review their applications under a priority review pathway.

Drugs that will be afforded this status are included in the list of 48, among them therapies for cancer, rare diseases, cardiovascular conditions and further therapy areas.